The INTERNATIONAL JOURNAL OF HEMATOLOGY, published by SPRINGER JAPAN KK, serves as a critical platform for advancing research in the field of hematology. With a prestigious history spanning over three decades from 1991 to 2024, this journal is recognized for its impactful contributions, evidenced by its Q2 category ranking in Hematology for 2023, and its notable position at rank #71 out of 137 in the Scopus Medicine Hematology category. Researchers and professionals within the hematology community benefit from the journal's rigorous peer-reviewed articles that cover a wide range of topics, including clinical studies, basic research, and novel therapeutic strategies. Though currently non-open access, it provides essential insights and findings to an audience passionate about the latest advancements in blood disorders and treatments. Situated in Japan, the journal not only showcases high-quality research but also fosters a global exchange of knowledge in hematology, making it a significant resource for scholars, practitioners, and students alike.

Cancer Research and Treatment is a premier academic journal published by the Korean Cancer Association that focuses on advancing scientific knowledge and clinical practices in the fields of cancer research and oncology. With an ISSN of 1598-2998 and an E-ISSN of 2005-9256, the journal showcases cutting-edge research articles, clinical trials, and comprehensive reviews that address the multifaceted challenges in cancer treatment and management. Published in South Korea, this journal has established itself as a critical resource, evidenced by its Q1 rank in Oncology and Q2 rank in Cancer Research, reflecting its influence and stature within the academic community. The impact of research disseminated through Cancer Research and Treatment is underscored by its significant percentile rankings in Scopus, with notable positions in both the pharmaceutical and biological sectors. This journal aims to bridge the gap between laboratory research and clinical application, providing a platform for researchers, healthcare professionals, and students to enhance their understanding of cancer-related innovations and therapeutic strategies. Readers will benefit from rich content that not only discusses the latest advancements but also engages with pressing global health issues related to cancer.

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

Hematology Transfusion and Cell Therapy, published by Elsevier, is a leading Open Access journal dedicated to advancing the fields of hematology, immunology, and transfusion medicine. Since its establishment in 2018, this journal has provided a vital platform for sharing innovative research and clinical advancements in the management of blood disorders and cellular therapies. Based in Brazil, it attracts a global audience, facilitating access to high-quality research that influences clinical practice and policy. With a current impact factor that places it in the Q3 category for both hematology and immunology as of 2023, the journal is recognized for its rigorous peer-review process and commitment to disseminating significant findings. By featuring a diverse range of articles, from original research to reviews, Hematology Transfusion and Cell Therapy aims to foster collaboration and knowledge sharing among researchers, professionals, and students alike, empowering them to tackle emerging challenges in their fields.

Pediatric Nephrology, published by Springer, is a leading international journal dedicated to advancing the field of pediatric nephrology and enhancing the health of children with renal disorders. With its ISSN 0931-041X and E-ISSN 1432-198X, this esteemed journal has been in circulation since 1987 and has established itself as a vital resource for researchers and clinicians alike. Featuring a robust impact factor and categorized in Q1 for Pediatrics, Perinatology and Child Health, and Q2 for Nephrology, Pediatric Nephrology stands at the forefront of medical literature, reflecting its commitment to disseminating high-quality research. The journal is particularly noted for its comprehensive scope, encompassing clinical studies, innovative treatments, and cutting-edge research findings that shape pediatric kidney care. Located in Germany and reaching a global audience, this journal not only supports the academic community but also plays a crucial role in improving health outcomes for children worldwide. Access to its valuable content is essential for any practitioner or researcher invested in the evolving landscape of pediatric medicine.

Cancer Reports, published by WILEY, is an esteemed open-access journal dedicated to the field of oncology and cancer research. With a focus on disseminating impactful research findings since its transition to fully open access in 2021, Cancer Reports aims to facilitate knowledge sharing among researchers, clinicians, and healthcare professionals globally. The journal is positioned within the Q3 quartile for both Cancer Research and Oncology categories as of 2023, reflecting its commitment to quality and relevance in a competitive publishing landscape. With an ISSN of N/A and an E-ISSN of 2573-8348, the journal showcases studies across diverse aspects of cancer biology, treatment modalities, and patient care strategies. Located in the United Kingdom at 111 River St, Hoboken 07030-5774, NJ, Cancer Reports strives to contribute to the advancement of cancer research and improve health outcomes for patients worldwide, making it a pivotal platform for scholars and practitioners in the oncology community.

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, published by Mary Ann Liebert, Inc, stands at the forefront of research in the realms of ophthalmology and pharmacology. Established in 1985 and converging until 2024, this esteemed journal is dedicated to advancing the understanding of ocular pharmacology, drug therapies, and therapeutic approaches in the treatment of eye diseases. With an impressive impact factor and categorized in the Q2 quartile for both Ophthalmology and Medical Pharmacology, it showcases pivotal research in the field, reflecting its rank of #31 among 137 in Ophthalmology and #109 among 272 in Medical Pharmacology per Scopus metrics. Although it follows a subscription-based model, the journal provides critical insights and empirical studies that foster innovation and collaboration for researchers, professionals, and students alike in the pursuit of improving ocular health.

PARKINSONISM & RELATED DISORDERS, published by Elsevier Science Ltd, is a prominent peer-reviewed journal dedicated to advancing the understanding of Parkinson's disease and related neurodegenerative disorders. With an impact factor placing it in the Q2 category across multiple fields including Geriatrics and Gerontology and Neurology for 2023, this journal serves as a crucial platform for researchers, healthcare professionals, and students alike. Covering an array of topics from clinical trials to innovative therapeutic strategies, it aims to disseminate valuable insights that can improve patient care and outcomes. While it remains a subscription-based journal, its relevance is underscored by its consistent rankings in Scopus, where it ranks 105th in Clinical Neurology and 35th in Geriatrics and Gerontology. Authored by top scholars in the field, PARKINSONISM & RELATED DISORDERS continues to contribute significantly to the body of knowledge surrounding these debilitating conditions, facilitating the exchange of cutting-edge research and fostering collaboration within the scientific community.

BLOOD CELLS MOLECULES AND DISEASES is a prominent multidisciplinary journal published by Academic Press Inc., Elsevier Science, specializing in the fields of hematology, molecular biology, and cell biology. With an ISSN of 1079-9796 and an E-ISSN of 1096-0961, this journal serves as a vital resource for researchers, professionals, and students exploring the complex interplay between blood cells and their corresponding molecular pathways in disease states. Spanning topics from cellular mechanisms to therapeutic advancements, BLOOD CELLS MOLECULES AND DISEASES holds a commendable reputation with a 2023 category quartile ranking of Q2 in Hematology and Q3 in several related fields. This journal not only provides a platform for the dissemination of innovative research but also fosters collaboration and knowledge exchange within the scientific community. As it converges from 1995 to 2025, the journal continues to impact the medical and biological sciences significantly, making it an essential tool for advancing our understanding of hematologic diseases.

Blood Science is a distinguished peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the dynamic field of hematology. Since its inception, the journal has aimed to disseminate high-quality research and innovative findings that contribute to our understanding of blood-related health issues. With the ISSN 2543-6368, it offers a platform for academic discussions and breakthroughs in various subfields including hematopathology, blood disorders, and transfusion medicine. As of 2023, Blood Science is ranked in the third quartile (Q3) within the hematology category, indicating a burgeoning influence among its peers, with a Scopus rank of #101 out of 137 journals, placing it in the 26th percentile. Although it is not an open-access journal, it provides essential insights and valuable data for researchers, healthcare professionals, and students alike, enhancing the collective knowledge and practices in hematology. With a publication period spanning from 2019 to 2024, Blood Science remains committed to fostering the advancement of blood science research and enhancing patient care methodologies.